Form 4: Amneal Pharmaceuticals Executive Vice President Tasos Konidaris Reports Stock Transactions
SEC Form 4 Filing
Executive Vice President and CFO of Amneal Pharmaceuticals, Tasos Konidaris, reports the vesting of restricted stock units and subsequent tax withholding.
Summary
- On March 12, 2024, Tasos Konidaris, Executive Vice President & CFO of Amneal Pharmaceuticals, reported transactions involving Class A Common Stock.
- 87,720 restricted stock units vested, resulting in the acquisition of an equal number of shares.
- 30,790 shares were withheld to satisfy tax obligations at a price of $5.31 per share.
- Following these transactions, Konidaris directly owns 527,316 shares of Class A Common Stock.
- The restricted stock units were granted on March 12, 2020, and vest in four equal annual installments.
Sentiment
Score: 6
Explanation: Neutral sentiment as it reflects routine executive compensation and tax obligations.
Positives
- The vesting of restricted stock units indicates a continued alignment of the executive's interests with those of the shareholders.
Industry Context
Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions, which are closely monitored by investors.
Stakeholder Impact
- Shareholders may view the vesting of restricted stock units as a sign of continued executive commitment.
Key Dates
| Date | Description |
|---|---|
| 03/12/2020 | Reporting person was granted 350,877 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 03/12/2024 | Date of restricted stock units vesting and tax withholding. |
| 03/14/2024 | Date of signature on the SEC Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.